RxDoctor Payments Data

Alisa Kniffen, APRN

Psychiatric/Mental Health · Kearney, NENPI 1811609555

Payments from drug & device makers

$948in general payments, 2019–2025

Across 31 payments — averaging $30.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$434
  • Otsuka America Pharmaceutical, Inc.$199
  • Alkermes, Inc.$150
  • Neurocrine Biosciences, Inc.$65
  • Supernus Pharmaceuticals, Inc.$29
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$29
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$948100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$948 in reported general payments places this provider in the 45th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$18,328
Medicare patients
58
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate23$70,751
CaplytaLumateperone Tosylate22$43,729
Abilify MaintenaAripiprazole11$30,350
Paliperidone ErPaliperidone59$7,176
Bupropion XlBupropion Hcl58$3,677
Clozapine25$2,771
Vilazodone Hcl19$2,315
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine26$1,939
Desvenlafaxine Succinate ErDesvenlafaxine Succinate48$1,829
Aripiprazole68$1,739
Olanzapine91$1,462
Mirtazapine88$1,214
Clonazepam97$1,030
Atomoxetine Hcl16$1,022
Risperidone67$938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$23$70,75123 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$29$43,72922 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$199$30,35011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →